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Whilst the development of chemotherapy and 
radiotherapy for Hodgkin lymphoma (HL) has resulted 
in high cure rates, long-term side effects of treatment 
including cardiovascular disease and second cancer 
represent a significant cause of morbidity and mortality 
for HL survivors. Since an increased risk of second cancer 
was first observed in HL survivors in the 1970s, progress 
has been made in quantifying this cancer risk (Figure 1), 
as well as identifying patient and treatment related factors 
influencing risk. These factors include age at treatment, 
site and dose of radiotherapy and chemotherapy, and 
smoking. Knowledge of second cancer risks has informed 
recent HL treatment strategies, namely the development of 
treatment regimens based on a reduction in the field and 
dose of radiotherapy and chemotherapy and risk-adapted 
therapy [1]. Despite such modifications, a recent analysis 
of a cohort of HL survivors in the Netherlands failed to 
demonstrate a reduction in second cancer risks in HL 
survivors treated in the 1990s when compared to earlier 
periods [2].
Approximately 20 years ago a family history of 
breast cancer was suggested as a possible influence on 
second cancer risk following HL [3]. Subsequent studies 
have attempted to quantify the impact of family history 
on second cancer risk in HL survivors, but have had 
limited power. Using a Swedish Family Cancer Project 
Database, we sought to gain insight into the risk of second 
cancer after a diagnosis of HL and its relationship to 
temporal changes in treatment regimens. Furthermore, we 
performed a detailed analysis of the influence of family 
history, as a surrogate for genetic susceptibility, on the risk 
of second cancer in patients with HL [4].
We identified 9,522 HL patients in Sweden from 
1965-2012, with a total of 1,215 second cancers observed 
in 1,121 patients. The risk of all second cancers was 
elevated after HL diagnosis, with a standardised incidence 
ratio (SIR) of 2.39, corresponding to an absolute excess 
(AER) risk of 71.2 cases per 10,000 person-years. Non-
Hodgkin lymphoma, breast cancer, non-melanoma skin 
cancer, leukaemia and colorectal cancer contributed the 
most to AERs, accounting for 16.2%, 14.5%, 12.9%, 
11.4%, 9.7% and 7.6% of the excess cancer risks 
respectively. We confirmed the findings of previous studies 
demonstrating distinct differences in second cancers risk 
depending on cancer site, sex and age at HL treatment. 
Given an absence of individual treatment data in 
the Swedish Cancer Registry and that treatment principles 
for HL in Sweden are broadly similar to those of other 
Western countries, we analysed second cancer risk for HL 
patients diagnosed in the time periods of 1965 to 1977, 
1978 to 1988, and 1989 to 2000 as a proxy for treatment 
strategy. We found no evidence for significant change in 
the risk of second cancer, supporting the recent findings of 
Schaapveld et al [2]. Possible explanations for this finding 
include an increase in the proportion of patients exposed 
to chemotherapy in later time periods, the impact of 
screening, an interaction between less toxic chemotherapy 
and second cancer risk, and the time periods analysed not 
accurately capturing the reduction in treatment intensity.
We also found an increase in second cancer risk in 
HL survivors who had a first-degree relative (FDR) with 
cancer. This elevated risk was correlated with the number 
of FDRs affected with cancer, with respective SIRs being 
2.67 and 3.40 for patients with one and two or more 
affected FDRs. For lung, colorectal and breast cancer, 
we observed a 3.3-fold, 2.1-fold, and 1.8-fold increase 
in risk in HL survivors with a FDR with the respective 
site-specific cancer. It was notable that a greater than 
additive interaction between family history of lung cancer 
and HL treatment was observed, which may be explained 
by environmental factors such as smoking. These 
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Figure 1: Second cancer in HL survivors in different 
studies [2, 4, 7, 8]. Risk estimates from the British cohort 
calculated from HL patients treated with combined modality 
therapy whereas other cohorts include any treatment modality. 
Risk estimate for leukaemia in USA, refers to acute myeloid 
leukaemia. No risk estimate for colorectal cancer in HL survivors 
for USA study.
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findings provide indirect evidence for a role in genetic 
predisposition in determining second cancer risk and are 
supported by the example of retinoblastoma, in which 
individuals with hereditary retinoblastoma have a much 
higher risk of radiotherapy-induced second malignancy 
compared with those with sporadic disease [5]. Whilst no 
high impact cancer susceptibility gene has been identified 
in HL, polygenic susceptibility may provide an alternative 
model by which germline genetics influence second cancer 
risk [6].
Our study further substantiates the significant cancer 
risks associated with survivorship from HL and that these 
risks are modified by a number of factors including 
family history of cancer. Understanding the biological 
mechanisms of such associations will further our 
knowledge of carcinogenesis, in the hope of developing 
novel therapeutic strategies. Moreover, such information 
has current direct clinical relevance in planning risk-
adapted therapy, implementing strategies to reduce second 
cancer risk such as smoking cessation and informing the 
screening of HL survivors.
Amit Sud: Division of Genetics and Epidemiology, The 
Institute of Cancer Research, London, UK
Correspondence to: Amit Sud, email amit.sud@icr.ac.uk
Keywords: Hodgkin lymphoma, second cancer risk, family 
history
Received: August 30, 2017
Published: September 14, 2017
REFERENCES
1. Johnson P, et al. N Engl J Med. 2016; 374: 2419-29.
2. Schaapveld M, et al. N Engl J Med. 2015; 373: 2499-511.
3. Nichols KE, et al.  J Clin Oncol. 1999; 17: 1259-66.
4. Sud A, et al.  J Clin Oncol. 2017; 35: 1584-90. 
5. Draper GJ, et al. British Journal Cancer. 1986; 53: 661-71. 
6. Ma YP, et al. Blood. 2012; 119: 1029-31. 
7. Swerdlow AJ, et al.  J Clin Oncol. 2011; 29: 4096-104. 
8. Singh P, et al.  J Clin Oncol. 2016; 34: e19014. 
Copyright: Sud et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original author and 
source are credited.
